Company
Apimeds Pharmaceuticals US, Inc. (APUS)
Standardized SEC financial data for Apimeds Pharmaceuticals US, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001894525 · NYSE · Pharmaceutical Preparations.
Return on equity
-3.9%
Free cash flow
-$9.0M
Current ratio
1.31×
EPS (diluted)
$-0.55
Income statement
| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| R&D expense | $99K | — | $1.6M |
| SG&A expense | $649K | $1.3M | $10.3M |
| Operating income | -$747K |
Balance sheet
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $6K | $410K | $3K | $9.6M |
| Total current assets | — | $422K | $13K | $14.0M |
Cash flow
| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$628K | -$734K | -$8.9M |
| Capital expenditures | — | — | $57K |
| Free cash flow | — | — |
Get APUS data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/APUS/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/APUS/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"